Source-grounded facts extracted from Definium Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Definium Therapeutics, Inc. shareholders approved Approval of the Equity Plan Amendment at the 2026-06-11 meeting.
“Proposal 3 – Approval of the Equity Plan Amendment The shareholders approved the Equity Plan Amendment by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 58,149,028 4,708,102 197,368 15,619,094”
Definium Therapeutics, Inc. shareholders approved Appointment of Auditor at the 2026-06-11 meeting.
“Proposal 2 – Appointment of Auditor The shareholders approved the appointment of KPMG LLP as the independent registered public accounting firm (auditor) of the Company until the 2027 Annual Meeting by the following votes: Votes For Votes Withheld Broker Non-Votes 78,579,054 94,538 -”
Definium Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-11 meeting.
“Proposal 1 – Election of Directors The Company’s seven nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone, and Roger Adsett, were each elected to serve as a member of the Board until the 2027 annual general meeting of shareholders (the “2027 Annual Meeting”) or until a successor has been duly elected or appointed, by the following votes: Company Board Nominee Votes For Votes Withheld Broker Non-Votes Robert Barrow 62,881,122 173,376 15,619,094 Dr. Suzanne Bruhn 62,503,873 550,625 15,619,094 Dr. Roger Crystal 60,056,178 2,998,320 15,619,094 David Gryska 62,760,423 294,075 15,619,094 Andreas Krebs 62,395,043 659,455 15,619,094 Carol A. Vallone 62,623,945 430,553 15,619,094 Roger Adsett 62,931,294 123,204 15,619,094”
Definium Therapeutics, Inc. reported financial results for fiscal quarter ended March 31, 2026.
“On May 7, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended March 31, 2026, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights.”
Definium Therapeutics, Inc.: Changed company name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc. via alteration of Notice of Articles (effective 2026-01-09).
“On January 9, 2026, the Company filed a Notice of Alteration with the Province of British Columbia Registrar of Companies to alter its Notice of Articles to change the Company’s corporate name from “Mind Medicine (MindMed) Inc.” to “Definium Therapeutics, Inc.””
Carrie Liao changed role as principal financial officer and principal accounting officer at Definium Therapeutics, Inc..
“Carrie Liao, the Company’s Chief Accounting Officer, will no longer serve as the Company’s principal financial officer and principal accounting officer.”
Brandi L. Roberts was appointed as Chief Financial Officer at Definium Therapeutics, Inc..
“had appointed Brandi L. Roberts as Chief Financial Officer, effective as of June 2, 2025 (the “Effective Date”).”
Definium Therapeutics, Inc. amended credit facility of up to $120.0 million with K2 HealthVentures LLC at the greater of (x) 10.25% and (y) the sum of (a) the Prime Rate as reported in T maturing April 1, 2029.
“Agreement”). The First Amendment and the Amended Credit Agreement provide for, among other things: (i) an aggregate principal amount of term loans (the “Term Loans”) of up to $120.0 million, consisting of (A) a new Restatement First Tranche Term Loan (as defined in the Amended Credit Agreement) of $42.0 million, which was funded on the Effective Date, a portion of”
Miri Halperin Wernli was terminated as Executive President at Definium Therapeutics, Inc..
“On January 10, 2025, Mind Medicine (MindMed) Inc. (the "Company") notified Miri Halperin Wernli, the Company's Executive President, that it was terminating her employment without cause, effective February 28, 2025, as the Company centralizes its management team in the United States to enhance collaboration and alignment with its strategic goals.”
Definium Therapeutics, Inc. entered into Purchase Agreement with certain investors valued at approximately $70.3 million (effective 2024-03-07).
“Also on March 7, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Investors agreed to purchase, and the Company agreed to sell 12,500,000 common shares (the “Private Placement Shares”), at a price of $6.00 per Private Placement Share, in a private placement transaction (the “Private Placement”).”
Definium Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the underwriters named therein valued at approximately $93.8 million (effective 2024-03-07).
“On March 7, 2024, Mind Medicine (MindMed) Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the underwriters named therein (the “Underwriters”), in connection with the issuance and sale by the Company in an underwritten offering (the “Offering”) of 16,666,667 common shares”
Definium Therapeutics, Inc. reported financial results for year ended December 31, 2023.
“MindMed Reports 2023 Financial Results and Business Updates --Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half of 2024-- --Initiated Phase 1 clinical trial of MM402 in Autism Spectrum Disorder (ASD)-- --Conference call to discuss year-end financial results at 8:00 a.m. EST--”
Definium Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income Net loss for the quarter ended September 30, 2023, was $17.9 million.
“Net loss for the quarter ended September 30, 2023, was $17.9 million, compared to $16.5 million for the same period in 2022.”
Definium Therapeutics, Inc. entered into Loan and Security Agreement with K2 HealthVentures LLC, as administrative agent and Canadian collateral agent, and the lenders referred to therein valued at $50.0 million in term loans (effective 2023-08-11).
“On August 11, 2023 (the “Closing Date”), Mind Medicine (MindMed) Inc. (the “Company”) and certain of its subsidiaries party thereto, as co-borrowers (together with the Company, the “Borrowers”), entered into a Loan and Security Agreement (the “Loan Agreement”) with the lenders referred to therein (the “Lenders”), K2 HealthVentures LLC (“K2HV”), as administrative agent and Canadian collateral agent for the Lenders, and Ankura Trust Company, LLC, as collateral trustee for the Lenders.”
Definium Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
“On August 3, 2023, Mind Medicine (MindMed) Inc. (the “Company”) issued a press release (the "Press Release:) announcing its financial results for its fiscal quarter ended June 30, 2023”
Definium Therapeutics, Inc. shareholders approved Appointment of Auditor at the 2023-07-25 meeting.
“The shareholders approved the appointment of KPMG LLP as the auditor of the Company until the close of the 2024 Annual Meeting, by the following votes:”
Definium Therapeutics, Inc. shareholders approved Election of Directors at the 2023-07-25 meeting.
“The Company’s six nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, and Carol A. Vallone, were each elected to serve as a member of the Company’s Board of Directors (the “Board”) until the 2024 annual general meeting of shareholders (the “2024 Annual Meeting”) and until his or her successor is duly elected or qualified, by the following votes:”
Definium Therapeutics, Inc. shareholders approved Appointment of KPMG LLP as auditor of the Company until the close of the 2024 Annual Meeting at the 2023-06-21 meeting.
“The shareholders approved the appointment of KPMG LLP as the auditor of the Company until the close of the 2024 Annual Meeting, by the following votes: Votes For Votes Against Votes Abstain 14,857,596 394,019 1,078,880”
Definium Therapeutics, Inc. shareholders approved Election of Directors: Company Board Nominees and FCM MM Holdings, LLC Nominees at the 2023-06-21 meeting.
“The Company's six nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, and Carol A. Vallone, were each elected to serve as a member of the Company's Board of Directors (the "Board") until the 2024 annual general meeting of shareholders (the "2024 Annual Meeting") and until his or her successor is duly elected or qualified, by the following votes: Company Board Nominee Votes For Votes Withheld Robert Barrow 8,154,619 6,260,614 Dr. Suzanne Bruhn 10,708,185 3,707,052 Dr. Roger Crystal 8,208,815 6,206,151 David Gryska 12,248,893 2,166,343 Andreas Krebs 8,099,276 6,315,960 Carol A. Vallone 8,125,466 6,289,772 FCM MM Holdings, LLC Nominee Votes For Votes Withheld Dr. Scott Freeman 6,023,932 7,779,083 Dr. Farzin Farzaneh 6,022,144 7,780,172 Vivek Jain 5,950,387 7,852,629 Alexander J. Wodka 5,921,398 7,881,619”
Definium Therapeutics, Inc. updated its the quarter ended March 31, 2023 guidance (reaffirmed).
“Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2023.”
Brigid A. Makes departed as Director at Definium Therapeutics, Inc..
“On April 15, 2023, after extensive consideration and discussion with the Board of Directors (the “ Board ”) of Mind Medicine (MindMed) Inc. (the “ Company ”), Brigid A. Makes provided notice to the Board of her decision not to stand for re-election at the Company’s 2023 annual general meeting of shareholders (the “ Annual Meeting ”).”
Definium Therapeutics, Inc. updated its the full-year ended December 31, 2022 guidance (reaffirmed).
“today reported its financial results for the full-year ended December 31, 2022”
Definium Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $16.5 million.
“The net loss for the three months ended September 30, 2022 was $16.5 million”
Suzanne Bruhn was appointed as Director at Definium Therapeutics, Inc..
“On August 11, 2022, the Board appointed Suzanne Bruhn, Ph.D. to the Board, filling the vacancy left by the resignation of Dr. Halperin Wernli, effective immediately.”
Miri Halperin Wernli resigned as Director at Definium Therapeutics, Inc..
“On August 11, 2022, Miri Halperin Wernli, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she is resigning from the Board as of August 11, 2022.”
Schond Greenway was appointed as Chief Financial Officer at Definium Therapeutics, Inc..
“On May 23, 2022, Mind Medicine (MindMed) Inc. (the “Company”) announced the appointment of Schond Greenway as the Company’s Chief Financial Officer, effective May 23, 2022”
Sarah Y. Vinson departed as Director at Definium Therapeutics, Inc..
“On March 24, 2022, Sarah Y. Vinson, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she will not stand for re-election as a director of the Company at its 2022 Annual Meeting”
David D. Guebert departed as Chief Financial Officer at Definium Therapeutics, Inc..
“On March 25, 2022, David D. Guebert and the Company agreed to a separation from the Company with Mr. Guebert’s last day of employment on March 31, 2022.”
Stephen Hurst resigned as Director at Definium Therapeutics, Inc..
“On January 5, 2022, Mr. Stephen Hurst, a member of the board of directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”), notified the Board of his decision to resign from the Board, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.